Christian Grohe

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 171 publications

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study.

Journal: Clinical lung cancer

Published: March 26, 2026

Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry.

Sex-Specific Phenotypes and Outcomes in Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease: Results from the INSIGHTS-ILD Registry.

Journal: Respiration; international review of thoracic diseases

Published: December 31, 2025

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.

ADC Target Profiling in NSCLC: Generalizable AI Separates TROP-2 and cMET Phenotypes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 25, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: November 13, 2025

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).

PET/CT-guided management of immune checkpoint blockade and multi-modal profiling following treatment in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 08, 2025

Mycobacterium florentinum pulmonary disease: a case report and review of the literature.

Mycobacterium florentinum pulmonary disease: a case report and review of the literature.

Journal: BMC infectious diseases

Published: September 27, 2025

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

Beyond EML4: efficacy of targeted therapy in lung cancer patients with rare ALK fusions - a real-world retrospective analysis.

Journal: NPJ precision oncology

Published: September 05, 2025

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Feasibility and safety of nintedanib in combination with nivolumab in pretreated patients with advanced or metastatic adenocarcinoma of the lung - An AIO phase Ib/II trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 01, 2025

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.

Journal: Nature communications

Published: May 11, 2025

Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis.

Risk stratification as a guide to goal-oriented management of patients with fibrotic interstitial lung disease: a registry-based analysis.

Journal: ERJ open research

Published: April 25, 2025

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 13, 2025

Showing 1-12 of 171

Last Updated: 09/26/2026